Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 17, 2025

Micron Biomedical secures funds for needle-free vaccine development

Micron Biomedical has secured over $16m in a Series A3 financing round to expand the commercial manufacturing of its needle-free vaccines.

Continue
The company announced plans for the first Phase II trial of its needle-free measles/rubella vaccine. Credit: Nappy on Unsplash.
January 16, 2025

FDA clears Axcynsis’ AT03-65 IND for CLDN6-positive solid tumours

The company is set to launch a multicentre Phase I trial in the US in the first quarter of this year. Credit: Lucas Vasques on Unsplash.
January 15, 2025

Cycle expands MS treatment portfolio with Banner Life Sciences acquisition

The acquisition involves the inclusion of multiple sclerosis therapy, BAFIERTAM. Credit: Robina Weermeijer on Unsplash.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals December 31, 2024

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Pharmaceutical Business Review

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Popular

  1. JW Therapeutics’ Carteyva receives breakthrough therapy status for r/r LBCL
  2. RheumaGen secures $15m in Series A funding to advance RA therapies
  3. Parvus and Resilience expand partnership to develop IBD drug candidate
  4. FDA grants priority review to Dizal’s sunvozertinib NDA for NSCLC treatment
  5. Star Therapeutics’ von Willebrand disease therapy gains FDA fast track status

PRESS RELEASES

Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation